A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC

Clinical trial NCT05766410 · RECRUITING

Trial details

NCT number: NCT05766410
Sponsor: National Taiwan University Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer Hormone Receptor-positive Breast Cancer Hormone Therapy

Start date: 2022-09-16
Primary completion: 2025-09-30
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.